The Changes of Lipid Metabolism in Advanced Renal Cell Carcinoma Patients Treated with Everolimus: A New Pharmacodynamic Marker?

BACKGROUND: Everolimus is a mammalian target of rapamycin (mTOR) inhibitor approved for the treatment of metastatic renal cell carcinoma (mRCC). We aimed to assess the association between the baseline values and treatmentrelated modifications of total serum cholesterol (C), triglycerides (T), body m...

Descripción completa

Detalles Bibliográficos
Autores principales: Pantano, Francesco, Santoni, Matteo, Procopio, Giuseppe, Rizzo, Mimma, Iacovelli, Roberto, Porta, Camillo, Conti, Alessandro, Lugini, Antonio, Milella, Michele, Galli, Luca, Ortega, Cinzia, Guida, Francesco Maria, Silletta, Marianna, Schinzari, Giovanni, Verzoni, Elena, Modica, Daniela, Crucitti, Pierfilippo, Rauco, Annamaria, Felici, Alessandra, Ballatore, Valentina, Cascinu, Stefano, Tonini, Giuseppe, Carteni, Giacomo, Russo, Antonio, Santini, Daniele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4401714/
https://www.ncbi.nlm.nih.gov/pubmed/25885920
http://dx.doi.org/10.1371/journal.pone.0120427

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4401714/
https://www.ncbi.nlm.nih.gov/pubmed/25885920
http://dx.doi.org/10.1371/journal.pone.0120427

Ejemplares similares